Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index; 3 of the 25 sources its claims cite were checked for support.

Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis

Open access
Wang, Yanying, Lan, Boya, Zhang, Shuo, Mu, Yue, Mi, Jia, Yu, Jing, Zhan, Qun, Luo, Baoling, Lin, Fuyang, Teng, Jia, Wang, Xiuge, Yan, Guanchi · 2025 · Diabetology & Metabolic Syndrome

Abstract

Type 2 diabetes mellitus (T2DM) increases the risk of sarcopenia, but evidence on the effects of glucagon-like peptide 1 receptor agonist (GLP-1 RA) in skeletal muscle is limited and inconsistent. The study aimed to evaluate the skeletal muscle mass of GLP-1 RA in patients with type 2 diabetes. Randomized controlled trials of GLP-1 RA for sarcopenia with type 2 diabetes were identified by searching databases (up to July 6, 2025). Electronic databases (CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, Cochrane library, Web of Science, and Google Scholar), grey literature (Open Grey and Proquest) and reference lists of included articles were searched. The I 2 and τ 2 statistic was used to assess the heterogeneity. The random effects model was applied regardless of the heterogeneity. Funnel plots were used to assess publication bias. The results were evaluated by calculating the risk ratio (RR), mean difference (MD), and confidence interval (CI). The study included nine randomized controlled trials with a total of 1089 participants. GLP-1 RA significantly reduced weight-related changes and fat-related changes, including body weight (BW) (MD= -2.25, 95%CI: -6.99 to 1.89 P = 0.20), body mass index (BMI) (MD= -1.83, 95%CI: -3.88 to 0.23, P < 0.01), fat mass (FM) (MD= -8.00, 95%CI: -11.93 to -4.08, P < 0.01), body fat ratio (BFR) (MD= -2.76, 95%CI: -3.65 to -1.87, P < 0.01), visceral fat area (VFA) (MD = 0.74, 95%CI: -54.93 to 56.40, P < 0.05). In muscle-related changes, lean body mass (LBM) (MD = 4.61, 95%CI: -4.19 to 13.42, P = 0.31), and skeletal muscle index (SMI) (MD = 0.59, 95% CI: -0.69 to 1.86, P = 0.19) were not significantly different. GLP-1 receptor agonists, regardless of structure, have beneficial effects on body weight and fat content in type 2 diabetes with sarcopenia, but have no effect on reducing muscle mass. PROSPERO (CRD42023473528).

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of nine RCTs (1089 participants) found that GLP-1 receptor agonists did not significantly change lean body mass or skeletal muscle index in type 2 diabetes with sarcopenia, while some fat-related measures improved. The authors conclude GLP-1 RAs have beneficial weight/fat effects without reducing muscle mass, though evidence certainty and heterogeneity limit interpretation.

Key findings

  • Muscle outcomes showed no significant difference: lean body mass (LBM) MD = 4.61, 95% CI −4.19 to 13.42, P = 0.31, I² = 98.4%; skeletal muscle index (SMI) MD = 0.59, 95% CI −0.69 to 1.86, P = 0.19, I² = 73.6%.
  • Fat-related outcomes reportedly improved: fat mass MD = −8.00, 95% CI −11.93 to −4.08, P < 0.01; body fat ratio MD = −2.76, 95% CI −3.65 to −1.87, P < 0.01; BMI MD = −1.83, 95% CI −3.88 to 0.23, P < 0.05; VFA MD = 0.74, 95% CI −54.93 to 56.40, P < 0.05.
  • Body weight was not significant: abstract reports MD = −2.25, 95% CI −6.99 to 1.89, P = 0.20; results section reports MD = −2.55, 95% CI −6.99 to 1.89, P = 0.20.
  • Adverse reactions were not significantly different between GLP-1 RA and other drugs: RR = 79.9%, 95% CI 36.4% to 93.6%, P = 0.13, in 247 GLP-1 RA users and 247 non-users.

Methods

  • Systematic review and meta-analysis following PRISMA and Cochrane Handbook, registered in PROSPERO (CRD42023473528); searched CNKI, Wanfang, VIP, SinoMed, PubMed, EMbase, Cochrane Library, Web of Science, Google Scholar, grey literature, and reference lists up to July 6, 2025.
  • Included randomized controlled trials of adults ≥18 years with type 2 diabetes and sarcopenia receiving GLP-1 RA versus other hypoglycemic drugs; nine RCTs with 1089 participants were included, with follow-up of 12–24 weeks.
  • Random-effects meta-analysis using R 4.1.3, Hartung-Knapp adjustment, I² and τ² for heterogeneity, funnel plots/Egger’s test for publication bias, ROB 2.0 for risk of bias, and GRADE for certainty of evidence.

Limitations

  • Stated by the authors: the eligible RCT sample size was small; most studies followed participants for only 12 weeks, so long-term effects are unknown; limited data prevented confirming effects on skeletal muscle strength and physical function; the effect of age on muscle composition was not discussed.
  • Evident from the text: heterogeneity was high for several outcomes (LBM I² = 98.4%, BW I² = 93.4%, BMI I² = 94.2%, VFA I² = 75.3%, SMI I² = 73.6%), and subgroup analysis/meta-regression were limited because n ≤ 10 studies.
  • Evident from the text: there are internal inconsistencies, including “six studies” versus nine included studies, different BW effect estimates in the abstract and results, some confidence intervals crossing the null despite reported P < 0.05, and GRADE certainty described inconsistently for LBM/SMI.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13098-025-01877-4

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Flow chart of literature search and study selection
Fig. 1 Flow chart of literature search and study selectionCC BY-NC-ND · PubMed Central
Fig. 2 Risk of bias: (A) Risk of bias summary about each risk of bias item for each included study. (B) Risk of bias graph about each risk of bias item presented as percentages across all included studies
Fig. 2 Risk of bias: (A) Risk of bias summary about each risk of bias item for each included study. (B) Risk of bias graph about each risk of bias item presented as percentages across all included studiesCC BY-NC-ND · PubMed Central
Fig. 3 The association between GLP-1 RA and muscle changes: (A) muscle mass (LBM), (B) skeletal muscle index (SMI)
Fig. 3 The association between GLP-1 RA and muscle changes: (A) muscle mass (LBM), (B) skeletal muscle index (SMI)CC BY-NC-ND · PubMed Central
Fig. 4 The association between GLP-1 RA and weight changes: (A) body weight (BW), (B) body mass index (BMI)
Fig. 4 The association between GLP-1 RA and weight changes: (A) body weight (BW), (B) body mass index (BMI)CC BY-NC-ND · PubMed Central
Fig. 5 The association between GLP-1 RA and fat changes: (A) body fat mass (FM), (B) fat weight% (BFR), (C) visceral fat interval (VFA)
Fig. 5 The association between GLP-1 RA and fat changes: (A) body fat mass (FM), (B) fat weight% (BFR), (C) visceral fat interval (VFA)CC BY-NC-ND · PubMed Central
Fig. 6 Forest plot of incidence of adverse events between the two groups
Fig. 6 Forest plot of incidence of adverse events between the two groupsCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

2 Valid · 1 Not valid · 19 Not checked · 46 Own results and interpretations

41 more claims

Create a free account to see all 68 claims and to verify the 22 references still open.

See all claims — free account
  • It may state two separate claims as one. 8
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 16

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 10 · the rest aren’t loaded

5 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Show all 63 references

Research works printed but not linked: 5

  1. McDonald N, Schoenebeck S, Forte A. Reliability and inter-rater reliability in qualitative research: norms and guidelines for CSCW and HCI practice. Proc ACM Hum Comput Interact. 2019;3CSCW:1–23.
  2. Deeks JJ, Higgins JP, Altman DG et al. Chapter 10: chap. 10: analysing data and undertaking meta-analyses. Cochrane Handb Syst Reviews Interventions [Internet] 2024; 6.
  3. Hongmin Z, Jinlin W, Xingyu Z, Mei Y. The effect of liraglutide combined with Metformin on the function of islet β cells and visceral fat level in patients with type, type 2 diabetes and obesity. Chin J Cells Stem Cells (Electronic Edition). 2019;9(03):144–8.
  4. Xuejuan X, Xiaojun L, Jinsong C. Comparison of Metformin combined with insulin Detemir or liraglutide to treat type 2 diabetes mellitus with sarcopenia. Drug Evaluation. 2018;15(11):9–11.
  5. Xueding Z, Xiaoya W. Effects of smeglutide on skeletal muscle and visceral fat in obese patients with type 2 diabetes mellitus. Diabetes New World. 2025;28(8):1–4.

Cited by

See all 10

Metadata

Authors
Wang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., Wang, X., & Yan, G.
Affiliations
Changchun University of Chinese Medicine (CN)
Corresponding author
  • Wang, Xiuge
  • Yan, Guanchi
Venue
Diabetology & Metabolic Syndrome
Published
2025-08-06
Volume
17
Issue
1
Pages
315-315
ISSN
1758-5996 (ISSN-L)
OpenAlex
W4413027753
Cited by
8
References
63
Citations by year
2026: 6 · 2025: 2
FWCI
1.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Diabetology & Metabolic Syndrome (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Natural Science Foundation of Jilin Province Science and Technology Development Plan (YDZJ202501ZYTS253)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Keywords
type 2 diabetes, sarcopenia, GLP-1 receptor agonists, skeletal muscle mass, lean body mass, skeletal muscle index, body weight, body mass index, fat mass, visceral fat area, body fat percentage, weight loss, sarcopenic obesity, sarcopenic cachexia, sarcopenic frailty

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s13098-025-01877-4
The paper
Wang, Y., Lan, B., Zhang, S., Mu, Y., Mi, J., Yu, J., Zhan, Q., Luo, B., Lin, F., Teng, J., Wang, X., & Yan, G. (2025). Dionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis. Diabetology & Metabolic Syndrome. https://doi.org/10.1186/s13098-025-01877-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.